Equities

Medicenna Therapeutics Corp

MDNAF:QXE

Medicenna Therapeutics Corp

Actions
  • Price (USD)1.31
  • Today's Change0.114 / 9.46%
  • Shares traded48.57k
  • 1 Year change+254.04%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 17:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CAD
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments173421
Total Receivables, Net1.160.861.31
Total Inventory------
Prepaid expenses0.931.931.55
Other current assets, total------
Total current assets193623
Property, plant & equipment, net----0
Goodwill, net------
Intangibles, net0.060.060.07
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets193623
LIABILITIES
Accounts payable2.071.621.67
Accrued expenses0.792.180.95
Notes payable/short-term debt000
Current portion long-term debt/capital leases----0
Other current liabilities, total------
Total current liabilities2.863.802.62
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total113.16--
Total liabilities146.962.62
SHAREHOLDERS EQUITY
Common stock10110184
Additional paid-in capital119.497.93
Retained earnings (accumulated deficit)(106)(81)(71)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.020.060.17
Total equity5.192921
Total liabilities & shareholders' equity193623
Total common shares outstanding707056
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.